CervoMed’s (CRVO) Buy Rating Reaffirmed at D. Boral Capital

D. Boral Capital reissued their buy rating on shares of CervoMed (NASDAQ:CRVO) in a research note issued to investors on Tuesday,Benzinga reports. D. Boral Capital currently has a $10.00 price target on the stock.

A number of other equities analysts also recently commented on CRVO. HC Wainwright downgraded CervoMed from a “buy” rating to a “neutral” rating in a report on Tuesday, December 17th. Roth Capital upgraded shares of CervoMed to a “strong-buy” rating in a report on Thursday, December 5th. Roth Mkm began coverage on shares of CervoMed in a research note on Friday, December 6th. They set a “buy” rating and a $45.00 target price on the stock. Canaccord Genuity Group reduced their price target on shares of CervoMed from $65.00 to $12.00 and set a “buy” rating on the stock in a research report on Wednesday, December 11th. Finally, Brookline Capital Management lowered shares of CervoMed from a “strong-buy” rating to a “hold” rating in a report on Tuesday, December 10th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $33.14.

CervoMed Stock Performance

Shares of CRVO stock opened at $2.36 on Tuesday. The business has a 50-day moving average of $2.22 and a 200 day moving average of $8.22. CervoMed has a 1-year low of $1.80 and a 1-year high of $26.38.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the company. Barclays PLC raised its position in shares of CervoMed by 323.6% in the 3rd quarter. Barclays PLC now owns 7,748 shares of the company’s stock worth $113,000 after acquiring an additional 5,919 shares in the last quarter. Perigon Wealth Management LLC purchased a new position in shares of CervoMed in the 4th quarter worth approximately $147,000. State Street Corp raised its stake in shares of CervoMed by 28.1% during the 3rd quarter. State Street Corp now owns 104,456 shares of the company’s stock worth $1,525,000 after acquiring an additional 22,903 shares in the last quarter. Geode Capital Management LLC lifted its position in CervoMed by 13.9% during the third quarter. Geode Capital Management LLC now owns 114,934 shares of the company’s stock valued at $1,678,000 after acquiring an additional 14,042 shares during the last quarter. Finally, Citizens Financial Group Inc. RI grew its holdings in CervoMed by 13.2% in the third quarter. Citizens Financial Group Inc. RI now owns 30,509 shares of the company’s stock worth $445,000 after purchasing an additional 3,553 shares during the last quarter. 25.15% of the stock is owned by hedge funds and other institutional investors.

About CervoMed

CervoMed Inc, a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery.